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6Abstract 
Background: Drug use in pregnancy is common and both pregnant women and their 
physicians are in need of appropriate information for decision-making regarding drug 
therapy. However, uncertainty about the risks of drug use in pregnancy could result in 
restrictive attitudes to prescribing medicines and to their use. 
Purpose: To examine attitudes of and needs for medicines information among 
pregnant women and physicians. 
Materials and methods: Four studies based on three different methods were included; 
I: a descriptive study comparing drug advice regarding pregnancy from two 
commonly used sources: the Norwegian Drug Information Centres (DICs, named 
RELIS) and the product monographs in Felleskatalogen (FK), II: a survey among 
physicians who consulted RELIS for information on patient-specific drug use during 
pregnancy, III: interviews of pregnant women with epilepsy (WWE) using 
antiepileptic drugs (AEDs), IV: a survey among women attending ultrasound 
examination in gestation weeks 17-19 and their respective general practitioners (GPs). 
Results: Commonly used sources of information differed in advice regarding drug use 
in pregnancy. RELIS was a valued service among physicians and most advice had a 
clinical impact on therapeutic decisions. Pregnant WWE were confident in using 
AEDs through communication with their neurologist, but were concerned about dose 
adjustments. Pregnant women had higher teratogenic risk perceptions and lower 
confidence in use of medicines compared to their GPs. Phrasing of information texts 
may have influenced teratogenic risk perceptions. 
Conclusions and further implications: Deciding whether or not to prescribe or use 
medicines in pregnancy may be influenced by teratogenic risk perceptions, phrasing of 
medicines information, differences in advice between sources of information and 
availability of patient-specific and producer-independent medicines information. 
Physicians should aim to tailor the information to the pregnant woman’s risk 
perception level and desire for information. 
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1. INTRODUCTION 
1.1. Use of drugs in pregnancy 
Pregnant women, like women in general, use drugs to manage chronic diseases and to 
treat acute or pregnancy-induced symptoms (1). Based on results from drug utilization 
studies performed during the last 15 years, medication exposure during pregnancy is 
common, with frequencies varying from 39 - 99% (2-21). Table I provides an 
overview of studies published between 1999 and 2012, stating frequency of drug use 
and the most commonly used medicines. The drug utilization studies were performed 
solely in Western countries, and the studies reveal large variations in findings 
regarding frequency of drug use and the type of drugs used. This result may be related 
to differences in methodology, as well as country-specific differences (22). 
Furthermore, methodology has changed over time. Interviews or questionnaire 
surveys, with limited sample size, were commonly used methods in studies performed 
in the seventies and eighties (22, 23). Prescription drug databases (PDD) have become 
more common in drug utilization studies from 2000 onwards. Such studies provide 
opportunities for large sample sizes, but will not include use of over-the-counter 
(OTC) drugs, and do not measure actual drug use (24).  
 Use of herbal medicines is also frequent among pregnant women (25-28) and 
they are often used without informing the physician (27). In Norway, the herbal 
medicines most commonly used by pregnant women are ginger, cranberry and 
raspberry leaf (26, 27). Significantly, the documentation on safety of herbal medicines 
in pregnancy is even more limited than for modern medicines and, considering the 
sparse documentation on their effects, use of herbal medicines can seldom be 
recommended in pregnancy (26).  
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Frequency 
of drug 
use 
Period 
included in 
frequency
Most commonly used drugs N Drug history 
obtained
First Author Year Country
39 % P*
Antibiotics, Anti-infective gynecological drugs, 
ophtalmologics 2041 Interview Olesen (2) 2001 Denmark
44 % 3 + P + 3 Antibiotics, gynaecological drugs, anti-asthmatics 16001 PDD Olesen (3) 1999 Denmark
46 % P
Antibiotics, gynaecological anti-infective agents, nasal 
preparations 43470 PDD Malm (4) 2003 Finland
56 % P Anti-infectives, respiratory drugs, gastrointestinal drugs 1945 Interview Nordeng (5) 2001 Norw ay
56 % P Antibiotics, analgesics, anti-asthmatics 1626 Medical records 
from a cohort
Riley (6) 2005 USA
58 % 3 + P + 3 Antibacterials, sex hormones, NSAIDs 102995 PDD Stephansson (7) 2011 Sw eden
64 % 3 + P Anti-infectives, respiratory drugs, opioid and nonopioid 
analgesics
152531 PDD Andrade (8) 2004 USA
70 % 3 + P Iron supplements, amoxicillin, progesterone 33343 PDD Gagne (9) 2008 Italy
75 % P Haematological drugs, nutritional drugs, tocolytics 9004 Interview Donati (10) 2000 Italy
79 % P No data 5412 PDD Bakker (11) 2006 The Netherlands
83 % 3 + P + 3 Sex hormones, penicillins, cough and cold preparations 106329 PDD Engeland (12) 2007 Norw ay
83 % P Analgesics, anti-infectives, antacids. 11545 Questionnaire Headley (13) 2004 UK
84 % P Paracetamol, drugs against heartburn, penicillins 1793 Questionnaire Nordeng (14) 2010 Norw ay
85 % 3 + P Antacids, antibacterials, oral iron 3937 PDD Irvine (15) 2010 Scotland
93 % P Prenatal vitamins, paracetamol, calcium carbonate 578 Interview Glover (16) 2003 USA
94 % P
Drugs acting on the alimentary tract and metabolism (ATC 
group A), genito-urinary system and sex hormones 
(group G), nervous system (group N)
911 Prescription data 
and questionnaires
Beyens (17) 2003 France
96 % P
Drugs acting on the alimentary tract and metabolism (ATC 
group A), nervous system (ATC-group N), blood and 
blood forming organs (group B)
23898 PDD Crespin (18) 2011 France
96 % P
Drugs acting on the alimentary tract and metabolism (ATC 
group A), blood and blood forming organs (group B), 
genito-urinary system and sex hormones (group G)
41293 PDD Egen-Lappe (19) 2004 Germany
96-97% 3 + P Paracetamol-based analgetics, multivitamins, antacids 140 Interview Henry (20) 2000 Australia
99 % P Iron, gastrointestinal drugs, dermatological drugs 1000 PDD Lacroix (21) 2000 France
PDD; prescription drug database
3 + P + 3; drug history during the period 3 months prior to conception to 3 months after birth
3 + P; drug history during the period 3 months prior to conception to birth
6 + P + 6; drug history during the period 6 months prior to conception to 6 months after birth
P; drug history during pregnancy only, * Purchase of at least one prescription drug during the 120 days before the interview
Table I. Overview of studies examining frequency of drug use in pregnancy (1999-2011).
1.2. Teratogenic drug effects  
For all pregnancies, there is a 2 – 4 % baseline risk of major birth defects (29). 
However, less than 1% of these defects can be attributed to teratogenic effects 
resulting from maternal drug use (30, 31). The remaining 99% of birth defects have 
other causes; 9% are thought to be caused by maternal disease such as diabetes, 
infections or alcohol abuse, 20-25% have a genetic cause, and for the rest (about 65%) 
the cause is unknown (31).  
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 Teratogens are agents that irreversibly change growth, structure or function of 
the embryo or fetus, and include viruses, environmental factors, chemicals and drugs 
(32). Only about 20 drugs or groups of drugs have been proven to be human teratogens 
(31, 33). Examples of drugs or groups of drugs with established or potential 
teratogenic effects are given in Table II.  
Agents acting on the renin-angiotensin system Estrogens
Antidepressants Oral contraceptives
Antiepileptic drugs Retinoids (isotretinoin)
Anti-cancer agents Carbimazole
Anxiolytics Lithium
Androgens Misoprostol
Coumarin derivatives (warfarin) Thalidomide
Table II. Examples of drug groups or drugs with potential for teratogenic effects.
From Buhimschi and Weiner (32).
Even for drugs with teratogenic effects, the vast majority of pregnancies with drug 
exposure will result in normal offspring (33). Drug dose, route of administration, 
duration of treatment and gestational timing are all determinants for teratogenic risk at 
drug exposure (34). A drug may be safe at one dosage, but may give teratogenic 
effects if the dose is increased above a threshold level. Systemic drug exposure is also 
related to the route of administration. For example, dermal administration will reduce 
the risk of teratogenic effects due to limited systemic absorption. For drugs with 
potential for teratogenic effects throughout pregnancy, increased duration of treatment 
may increase the risks for fetal defects (35).  
Timing of exposure, with respect to the different periods in fetal developmental, is 
an important factor for susceptibility to teratogenic drug effects (35). The time from 
conception until implantation of the embryo (up to 14 days post conception), is 
considered to be an “all or none” period, as damage to the embryo will result in either 
spontaneous abortion or in intact survival. After this period, organogenesis takes place 
and sensitivity to teratogens is particularly high due to the risk of structural 
malformations. However, even after organogenesis, fetal growth and organ function 
may be affected by drug exposure (36, 37). For example, use of Angiotensin-
13
Converting Enzyme (ACE) inhibitors or Angiotensin Receptor Antagonists (ARBs) in 
the second or third trimester may induce effects on the fetus such as oligohydramnios 
and renal failure (38).  
1.3. Assessing teratogenic drug effects  
Due to the ethical concerns of including pregnant women in randomized controlled 
clinical trials, drugs have rarely been tested on this population at the time of their 
introduction into the clinical setting (36). Animal studies on teratogenicity are 
requested prior to drug approval, but their ability to predict human teratogenicity is 
limited (37, 39). Assessment of teratogenic risks is therefore based on data that are 
gradually gathered after drug marketing, through epidemiological studies such as case-
control studies, cohort studies or studies of total populations (24, 40), in addition to 
spontaneous reports of birth defects to pharmacovigilance databases, case reports or 
case-series (40). An overview of epidemiological study- types and their respective 
limitations is provided in Table III.  
Examples Limitations
Cohort studies
a) Studies performed by teratology 
information centres (TIS) (prospective)          
b) Pregnancy registers, based on reports 
of drug exposure before the outcome is 
known (prospective)                                         
c) Pregnancy cohorts, such as The 
Norwegian Mother and Child Cohort Study 
(the MoBa study) (prospective)
Misclassification bias                              
Low case numbers obtained                   
Selection bias (loss to follow-up)      
Confounding by indication
Studies of total 
populations
a) Medical birth registers                                
b) Linking of prescription drug databases 
(PDD) with medical birth registers                 
Actual drug use or time of drug use is 
often unknown (PDD)                               
Over-the-counter drugs are not 
included (PDD)                                         
Recall bias in medical birth registers if 
exposure data are collected after birth  
Confounding by indication
Case-control 
studies
Misclassification bias                              
Bias towards reporting known                
teratogenic effects                                    
Recall bias                                            
Interviewer bias                                         
Low participation rate                             
Confounding by indication
Table III. Overview of types of epidemiological studies used to examine teratogenic drug effects 
and their respective limitations.
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Teratology information services (TIS) perform cohort- studies in which 
information on drug exposure during pregnancy is collected prospectively (37, 41). 
Pregnancy registries, established by pharmaceutical companies or independent 
research groups, prospectively enrol pregnant women with drug exposure. Examples 
of pregnancy registries are national, regional and international epilepsy and pregnancy 
registries (42). Pregnancy cohorts, such as the Norwegian Mother and Child Cohort 
Study (the MoBa study), which included all women giving birth in Norway from 1999 
to 2008, can estimate effects of a wide range of exposures during pregnancy. The 
MoBa study is based on participants’ answering questionnaires at several time points 
during pregnancy and up to 7 years after birth, providing possibilities for long-term 
follow-up. Questionnaires 1 and 3, filled out in gestation weeks 13-17, and week 30, 
respectively, ask for medical history and use of medicines in pregnancy (43, 44). 
One possibility of studying the total population is to link PDDs with medical birth 
registers. This results in large data sets; however, it does not provide data on actual 
drug use (24).  
Epidemiological studies have inherent limitations and study results should be 
interpreted in light of this. A combination of different epidemiological methods may 
provide the optimal overview of teratogenic risks of drugs (45). Importantly, 
conclusions on teratogenic causality cannot be drawn from single studies (24, 40) and 
causality can only be assumed if the frequency of birth defects in children of women 
using a specific drug significantly exceeds the baseline risk. Furthermore, the number 
of exposed cases needed to declare a drug free of significant teratogenicity is based on 
the specificity and frequency of the malformations studied (24, 37), and it is not 
possible to absolutely establish the risk of drug use in pregnancy (31).   
Due to the lack of systematic studies on pregnant women before drug approval, 
there is a delay in acquiring teratogenic risk information on new drugs (46). A study 
on drugs approved by the American Food and Drug Administration (FDA) since 1980 
found that the mean time for a drug initially classified as having an undetermined 
teratogenic risk to be assigned a more precise risk was 27 years. This was based on 
assessments by an expert advisory board. Moreover, the experts were unable to 
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determine the teratogenic risk of 98% of 172 drugs approved by the FDA between 
2000 and 2010 (47).   
1.4. Teratogenic risk perceptions  
Risk is the probability from 0 – 1 of an event, good or bad, occurring during a certain 
period of time (48). Risk factors, such as drugs, may contribute to the event, but are 
not necessarily the cause of the event (49). A perception may be defined as “the way in 
which something is regarded, understood, or interpreted” (50). It has been suggested 
that there is a correlation between risk perception and behaviour and that this 
relationship may vary over time for an individual (51). Furthermore, the concept of 
attitude consists of three interrelated components; affect, cognition and behaviour (52), 
indicating that attitudes too may influence risk perceptions and behaviour. The 
concepts of risk, risk perceptions, attitude and behaviour are therefore of importance 
for understanding teratogenic risk perceptions. 
Dealing with the concept of risk is part of everyday life. However, when 
pregnancy occurs, managing risks become more complex. Risk perceptions and 
attitudes also become more evident. The pregnant woman becomes responsible not 
only for her own well-being and most mothers put the needs of their baby first (53). 
There are cultural differences in views on pregnancy (54), but Western society’s 
increased focus on risks in pregnancy, including extensive lists of food and activities 
to be avoided in pregnancy, can lead to a state of hypervigilance and increased anxiety 
(55).  
Only about 1% of birth defects are caused by maternal drug use; however, 
people generally attribute unrealistically high teratogenic risks to the use of drugs (33). 
In particular pregnant women, but also health care providers, overestimate teratogenic 
risks (14, 56-62). For the physician, the consequence may be inadequate treatment of 
the pregnant woman’s acute or chronic disease (62). For the pregnant woman, 
overestimating teratogenic risks can impact decisions on whether to continue the 
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pregnancy or not after taking a drug (63), and whether or not to take medicines (64, 
65).  
So, what are the possible explanations for these unrealistically high teratogenic 
risk perceptions? The 1960s’ discovery of birth defects resulting from use of 
thalidomide in early pregnancy (the thalidomide tragedy) (66) resulted in an increased 
awareness of teratogenic effects caused by drug use. This resulted in mandatory 
systematic developmental toxicity testing of drugs (67), and development of systems 
for pharmacovigilance (68). It has been suggested that the thalidomide tragedy may be 
a cause of the increased teratogenic risk perceptions even today (14, 59). Furthermore, 
the media usually stress the risks related to use of medicines and not the benefits (69)- 
a factor which could influence attitudes to medicines use in pregnancy. Authorities 
generally warn against use of alcohol and tobacco during pregnancy (70), and it is 
possible that pregnant women perceive this to also include use of other exogenous 
substances, such as drugs. Furthermore, pregnant women’s risk perceptions and health 
decisions are influenced by individual factors, such as experiences and opinions and 
beliefs of family and friends (64, 71). 
 One of the physicians’ roles is to guide patients in weighing risk and benefits, 
based on available knowledge (72). The fact that there is scientific uncertainty 
regarding teratogenic risks of drug use in pregnancy may however increase physicians’ 
own perception of risk (73).  
1.5. Principles of drug prescribing in pregnancy
Therapeutic decisions in pregnancy must include balancing the risk of untreated 
maternal disease against the teratogenic risk of drug treatment (32, 33). However, as 
40% of pregnancies are estimated to be unplanned (74), unintended use of medicines 
in early pregnancy is common. Two different situations requiring counselling of 
pregnant women regarding drug use are therefore possible: 
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• Inadvertent exposure to drugs 
• Intended continuation or initiation of drug treatment in pregnancy 
In either situation, the reason for use of drugs may be a chronic disease (long-term 
treatment) or acute or pregnancy-related conditions (short-term treatment). However, 
physicians need to consider the different premises for counselling in the two situations 
(75). Table IV presents some management principles for the two situations.
Inadvertent exposure to drugs Intended continuation or initiation of drugs 
ŹObtain accurate details of exposure and 
gestational age
ŹDrugs should only be used if the expected 
benefits (usually to the mother) are greater than 
the potential risks (usually to the fetus)
ŹCheck for confounding family and 
personal medical history
ŹTry to avoid first trimester use
ŹObtain up-to-date information about 
published risks of the drug in humans
ŹUse drugs that have been used extensively in 
pregnancy, not new ones
ŹEmphasize background risk in 
counselling
ŹUse the minimum dose required to obtain 
the desired effect
ŹBe clear on what is known (absence of 
data does not equal no risk)
ŹAbsence of data does not imply safety
Table IV. Management principles of drug therapy in pregnancy.
From Henderson and Mackillop (75).
Planning drug therapy of chronic diseases before conception is important for optimal 
management in pregnancy (75). Pregnant women with chronic diseases must be 
informed that withholding treatment may increase maternal and fetal risks, including 
preterm births, intrauterine growth restrictions and stillbirths (76, 77). For example, in 
epilepsy, seizures can harm both the mother and her fetus, and this risk must be 
weighed against the teratogenic risks of antiepileptic drugs (AEDs) (78).  
The physiological changes of pregnancy result in several pharmacokinetic 
changes, such as reduced absorption and increased elimination of drugs. For example, 
the clearance of lamotrigine may increase to more than 300% of the baseline value by 
the early third trimester, requiring dose adjustment. Therapeutic drug monitoring 
before, during and after pregnancy is recommended to evaluate the need for dose 
adjustments of drugs with pregnancy-altered pharmacokinetics (75).  
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1.6. Sources of information on drug use during pregnancy  
In order to assess teratogenic risks, both pregnant women and physicians need 
adequate drug information (14, 65, 79). In the following, I will first outline drug 
information sources available to physicians, and thereafter those available to pregnant 
women. Drug information to other health care providers or to patients is not covered. 
1.6.1. Drug information sources for physicians  
A challenge for physicians is access to drug information that is both easily available 
and useful for counselling pregnant women (80). A lack of such information has been 
reported (81, 82) . Nonetheless, physicians report use of several sources for 
information regarding teratogenic drug risks (79, 82, 83). Figure I provides an 
overview of sources of information relating to drug use in pregnancy that are available 
to physicians. Some of the sources are presented in the following. 
                 
Summary of
product
characteristics
(SPC)
The literature  
(books, Internet-
based literature)
Evidence-based 
medicine
Colleagues
Teratology 
Information 
Services (TIS)
Drug Information 
Centres (DIC)
Pregnancy
classification
systems
Product 
monographs
    
Figure I. Sources of drug information relating to pregnancy that are available to physicians.
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1.6.1.1. Product-specific information (SPCs, product monographs) 
Pharmaceutical companies are obliged to provide information regarding use in 
pregnancy in the Summary of Product Characteristics (SPC) and Patient Information 
Leaflet (PIL). Product monographs are based on the information in the SPC and are 
intended as practical guidelines for clinical use. Examples of product monographs 
include the Physician’s Desk Reference (PDR) in the USA, and Felleskatalogen (FK) 
in Norway. Because of the lack of clinical trial- data on pregnant women, the 
regulations set by medical authorities as well as fears of litigation, product-specific 
information rarely states that a medicine is safe to use in pregnancy (84). 
Consequently, in these sources a contraindication in pregnancy does not always reflect 
an established teratogenic risk. Therefore, product-specific information sources are not 
suited for counselling patients regarding teratogenic risks. If they are consulted as the 
primary source, physicians may fail to prescribe necessary medicines (76, 85). To 
illustrate this, Figure II presents a comparison between the SPC-text regarding use in 
pregnancy of a 2nd generation antihistamine, loratadine (Clarityn TM) (86, 87), and a 
summary made by the Norwegian Drug Information Centres (DICs) regarding 
antihistamines for allergic rhinitis during pregnancy (88).  
Summary of product characteristics (SPC) 
for loratadin (Clarityn TM) (86,87).
Loratadine was not teratogenic in 
animal studies. The safe use of 
loratadine during pregnancy has not 
been established. The use of 
Clarityn Allergy Tablets during 
pregnancy is therefore not 
recommended.
RELIS (Norwegian Drug Information Centres).  
Safe medicines for pregnant and breast
feeding women with allergic rhinitis (88). 
(translated text)
The clinical experience with use of
2nd generation antihistamines
among pregnant women is now
extensive. This experience does
not indicate increased
teratogenic risks. 
Figure II. Texts regarding risks in pregnancy from a product-specific source (left) and a producer-
independent source (right). 
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As can be observed in the Figure, the product-specific source is restrictive regarding 
use in pregnancy, while the producer-independent source states safe use based on 
extended experience. This illustrates the possible consequences of utilizing only 
product-specific information for counselling pregnant women.  
1.6.1.2. Teratogen information services (TIS) and Drug information 
centres (DIC)  
TIS and DICs are available to health care providers in many countries worldwide. 
Both TIS and DIC aim to provide problem-oriented drug information, i.e. discussion 
of a specific patient problem rather than purely report findings from the literature. The 
information is generally provided by clinical pharmacologists, pharmacists or 
specialists in teratology, and the working method is similar to the concept of evidence-
based medicine (89, 90).  
The difference between DIC and TIS is that TIS is specialized for counselling 
teratogenic risks (76, 91, 92) while drug queries to DIC are not confined to pregnancy 
and lactation. DICs mainly provide services to health care providers, but in some 
countries also to the lay public (93, 94). TIS usually serve both health care providers 
and the public (92). In countries where a TIS is not established, questions regarding 
pregnancy are usually handled by DICs, which frequently receive questions on this 
topic (89, 95-98). In Norway, DIC (RELIS) was established in 1994 and questions 
from health care providers regarding drug use in pregnancy are answered by RELIS. 
Important consequences of advice provided by TIS have been documented. This 
includes prevention of congenital malformations and unnecessary pregnancy 
terminations, as well as a reduction of unrealistic concerns related to drug use (99). 
Correspondingly, the DIC services have been found to have an impact on clinical 
practice (89, 90, 93, 98, 100).  
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1.6.1.3. Pregnancy risk classification systems 
Some countries, for example USA, Australia and Sweden, have introduced pregnancy 
risk classification systems for drugs. The intention is to categorize drugs according to 
their teratogenic risks in order to guide physicians in their risk/benefit evaluation 
regarding drug prescription (34, 101).  The systems are set up by teratologists, 
gynaecologists and clinical pharmacologists (101). However, limitations with these 
classification systems have been identified. For example, 70% of medicines in the 
American FDA system are allocated to the same risk category (84); the systems do not 
distinguish between animal and human data (1); and there are major inconsistencies 
between different classification systems (34, 101).  Due to these shortcomings, the 
FDA pregnancy labelling system is currently changing to a narrative model that 
includes three elements: risk summary, clinical considerations and data (1, 84). This 
model is similar to that of the Swedish online database “Drugs and Birth Defects” 
(102).  
1.6.2. Drug information sources for pregnant women 
Patients are encouraged to take an active role in their own health care and participate 
in therapeutic decisions (103, 104), implying a need for access to appropriate 
medicines information. In line with this, pregnant women report needs for information 
about teratogenic risks of medicines (14, 65). They also report use of several 
medicines information sources (14, 105, 106) as presented in Figure III. Some of the 
sources are presented in the following. 
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Figure III. Sources of drug information relating to pregnancy that are available to pregnant women. 
1.6.2.1. Health care providers 
The physician and the pharmacist have important roles as providers of medicines 
information. Other health care providers have no such formal roles or expertise, and 
this section therefore focuses on physicians and pharmacists as sources of information. 
It should however be mentioned that midwives are commonly utilized as a source of 
general health information by pregnant women, and might therefore be consulted for 
advice regarding medicines use. No studies examining midwives’ attitude to medicines 
use during pregnancy have been identified, although others have found that midwives 
support use of complementary and alternative medicine, such as herbal medicines, 
during pregnancy (107).  
Studies have shown that pregnant women consider their physician to be an 
important source of drug information (65, 105). This implies possibilities for tailoring 
information according to individual needs, which can increase patient satisfaction and 
adherence to treatment (108). Furthermore, establishing trust in the patient-physician 
relationship may increase pregnant women’s confidence in physicians’ advice 
regarding drug therapy (105).  
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Community pharmacists are easily accessible for advice regarding drug related-
issues, including drug use in pregnancy (14). However, studies have found that 
community pharmacists do not always provide evidence-based or appropriate advice to 
pregnant women, and they frequently refer patients to their physicians without 
providing advice themselves (109-111). This may indicate inexperience in dealing 
with pregnancy-related drug information, or lack of appropriate sources of 
information. This type of counselling may therefore have potential for improvement. 
It should also be pointed out that physicians and pharmacists have different 
roles regarding provision of medicines information. The physician is the prescriber, 
making therapeutic decisions by interacting with the patient. Pharmacists are the 
medication specialists and should provide additional information when prescribed 
medicines are dispensed. They should ideally should support and complement the 
advice provided by the physician. A further role for pharmacists is to provide advice 
regarding use of OTC drugs to treat mild symptoms (109). Utilization of the 
complementary roles of physician and pharmacist could result in better provision of 
medicines information to pregnant women.
1.6.2.2. Patient information leaflets (PILs) 
PILs, accompanying each medicine pack, aim to inform patients on how to use the 
medicine. The PIL should be based on the SPC and the text should be phrased so that 
patients understand the content (103, 112). The PIL is the only written information 
every patient is guaranteed to receive about their medicines (113, 114) and is often the 
only source available when the patient actually takes the medicine (103).  
The PIL should contain information regarding risks at pregnancy and lactation 
(115, 116). However, as in SPCs and product monographs, use in pregnancy is rarely 
recommended due to the inherent limitations of establishing teratogenic risks (84), as 
illustrated with antihistamines in Section 1.6.1.1. In one focus- group study, the 
participating pregnant women stated that PILs are not useful as an information source 
due to vague texts such as “as far as it is known this drug can be used during 
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pregnancy” or “ask your physician” when the drug had already been prescribed by 
one. The consequence of such text formulations could be concerns that the drug is 
harmful (65).  
1.6.2.3. The Internet and media 
The Internet is frequently used by pregnant women in search of health-related 
information (106, 117, 118) and the number of websites containing such information is 
increasing (119). There are numerous commercial Norwegian Internet- sites that target 
pregnant women, and several of them offer opportunity to exchange experiences with 
others through discussion forums, for example “barnimagen.no” (120), 
“mammanett.no” (121) and “snartmamma.com” (122). There are also government- 
funded websites providing information to pregnant women (123), however, there is 
currently little information available on these websites.  
Pregnant women’s reported reasons for use of the Internet are search for general 
pregnancy information, and additional information to that already provided by health 
care providers (106), and that it is a quick and convenient source of information (117). 
Furthermore, some pregnant women report dissatisfaction with information or lack of 
time to discuss the matter with health care providers (106). In one study, half of the 
participating women reported that they used information on the Internet in decision-
making regarding pregnancy (106).  
An important limitation of Internet information is that data may be inaccurate or 
incomplete. Consequently, it may be difficult for patients to distinguish between 
websites of high and low quality (117). Although some pregnant women perceive 
health information on the Internet to be reliable (118), other studies have highlighted 
the problem of patients’ evaluation of the quality of information on websites, and the 
risk of receiving incorrect information (106, 117). As a result, many pregnant women 
report that they are confused by the information found on websites (117). 
The increasing use of the Internet as an information source influence patient-
physician relationships. Physicians may utilize this by guiding Internet- informed 
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patients to reliable and accurate websites (119, 124). This may result in patients 
becoming more empowered to make informed health care choices (119).    
The media, including social media such as Facebook and Twitter, contribute to 
peoples’ general knowledge and judgement of medical treatment. However, the 
media’s tendency to focus on negative drug-related effects and its search for 
sensationalism could have a substantial impact on pregnant women’s concerns about 
drug use (69, 76). A review article showed that studies with “positive” results, i.e. 
revealing an increased risk for teratogenic effect with a drug, are more likely to be 
cited in the medical literature than studies with “negative” results, i.e. not showing 
adverse effects on the fetus (125). Such citation bias is easily transferred to the lay 
media and, in general, drug warnings are cited by the media while the benefits of 
medicines use in pregnancy may not receive the same attention (69, 126).  A further 
example of the impact of the media was the 2005 publication of a study that found 
increased risks for cardiac malformations in children whose mothers had taken the 
SSRI paroxetine in early pregnancy. Following the vast media- coverage of this study, 
one TIS documented an immediate increase in calls from concerned women taking or 
planning to take paroxetine (69).  
1.6.2.4. TIS and DIC  
As also described in Section 1.6.1.2, TIS and DIC are available to pregnant and breast-
feeding women in some countries. TIS have been shown to prevent congenital 
malformations and unnecessary pregnancy terminations, in addition to correcting 
elevated risk perceptions related to drug use (99). In Norway, a web-based drug 
information service (www.tryggmammamedisin.no)- similar to a TIS- was established 
in 2011. The Norwegian DICs are responsible for this service. 
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1.7. Follow-up of pregnant women by the Norwegian health 
care system
In Norway, there are national clinical guidelines for antenatal care. Pregnant women 
should be cared for throughout pregnancy by a general practitioner (GP) and/or a 
midwife. A basic programme of eight check-ups is recommended, including an 
ultrasound examination between the 17th and 19th week of pregnancy. A health record 
card, which has a section for noting chronic diseases and/or current use of medicines, 
is filled out at each check-up by the GP or midwife (127).  
The Norwegian guidelines for obstetric aid recommend that women with 
chronic diseases such as epilepsy, diabetes and rheumatic diseases are offered 
expanded follow-up. For example, women with epilepsy (WWE) receive 
preconception counselling and regular counselling during pregnancy at the Neurology 
Clinic, ultrasound examination at 11-14 weeks’ gestation and expanded ultrasound 
examination at 18 weeks’ gestation, in addition to individually planned obstetric 
follow-up (128).  
1.8. Motivation for the studies and the author’s 
preconceptions  
The work included in this thesis is based on my experience from working in a 
Norwegian DIC. RELIS is a national network of four regional DICs in Norway, 
answering problem-oriented drug-related questions from health care providers (129). 
Approximately 13% of the questions to RELIS concern the use of drugs in pregnancy. 
When including questions regarding breast-feeding, these topics constitute 19% of all 
queries, as described in Figure IV. Importantly, 86% of the queries received by RELIS 
are patient-specific (130).  
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Figure IV. Categories of questions received by RELIS in 2012, n=2586. 
As previously described, RELIS launched a web-based drug information service 
(www.tryggmammamedisin.no) for pregnant and breast-feeding women in 2011. I 
have been involved in this project since its conception and I am currently the project 
leader. Questions regarding treatment of pain, allergic rhinitis, psychiatric conditions 
and asthma are frequently received at www.tryggmammamedisin.no (131).  
Because of the frequent queries to RELIS regarding drug use in pregnancy, I 
became interested in this particular aspect of drug information. I wanted to know more 
about how drug information on this topic should be disseminated according to the 
needs of the information users; physicians and pregnant women. 
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2. AIM 
The main aim of this thesis was to examine pregnant women’s and physicians’ 
attitudes to, and needs for, information regarding use of medicines in pregnancy. This 
was undertaken in four papers with the following aims: 
Paper I 
To compare two commonly used sources that provide advice to physicians regarding 
drug use in pregnancy; answers from RELIS, and information in the product 
monographs in FK. Furthermore, to describe the frequency of drug queries made to 
RELIS regarding the use of drugs during pregnancy. 
Paper II 
To examine physicians’ evaluations of quality, clinical impact and ranking of RELIS 
with regard to questions regarding drug use in pregnancy. 
Paper III 
To examine risk perceptions and needs for medicines information among pregnant 
WWE.  
Paper IV 
To examine and compare teratogenic risk perceptions and confidence in use of 
medicines by pairs of pregnant women and GPs, based on assessments of texts from 
PILs. 
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3. MATERIAL AND METHODS
The studies included in this thesis were performed using three different approaches, 
based on four different study populations. Table V provides an overview of design, 
data collection and study population of the individual studies. In the following, design 
of the individual studies will be briefly discussed with methodological considerations. 
Paper Design Data collection Study population
I Descriptive, comparative study
Categorization of advice 
regarding pregnancy from RELIS 
and FK for corresponding drugs
443 drug advice
II Survey
Questionnaire to physicians who 
consulted RELIS for information 
on patient-specific drug use 
during pregnancy 
117 physicians 
III Qualitative study
Individual in-depth interviews with 
pregnant women with epilepsy 
using antiepileptic drugs
10 women
IV Survey
Questionnaire to pregnant women 
attending ultrasound examination 
in weeks 17-19 of pregnancy and 
their GPs
171 women                              
74 GPs                                     
98 pairs of women and GPs
Table V. Methodological overview of the papers included in the thesis.
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3.1. The descriptive study (Paper I) 
3.1.1. Data collection 
All questions to RELIS regarding pregnancy received during 2003 and 2005 were 
included. Advice provided by RELIS was compared to the advice in the product 
monograph in FK for the respective drug. Comparison of advice was based on 
categorization to one of four categories:  
1. Can be used  
2. Risk-benefit assessment 
3. Should not be used  
4. No available information  
Substance name with ATC (Anatomical Therapeutic Chemical) code and the year of 
introduction of the generic substance in Norway was registered, in addition to the 
trimester or trimesters in question.  
3.1.2. Methodological considerations 
A possible bias was that one pharmacist at RELIS categorized most of the advice. 
However, a pilot test among physicians demonstrated acceptable agreement with the 
categorizations by the pharmacist (Kappa coefficient 0.67). There was a possibility for 
overestimation of discrepancies in the material as contraindications in FK are often a 
reason for seeking advice from RELIS.  
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3.2. The surveys (Papers II and IV) 
3.2.1. Recruitment of participants 
Paper II: A questionnaire was sent consecutively to physicians who consulted RELIS 
during a one- year period regarding patient-specific drug use in pregnancy.  
Paper IV: A questionnaire was handed out to women attending ultrasound 
examination between weeks 17 and 19 of pregnancy at the Ultrasound Laboratory at 
the Department of Gynaecology and Obstetrics at Haukeland University Hospital in 
Bergen, Norway. In the questionnaire, the woman provided the name of her GP and 
the GP’s clinic and a questionnaire was subsequently sent to the GP. A pilot study was 
carried out to estimate the number of participants needed in the main study. 
3.2.2. Data collection 
Paper II: The quality of service provided by RELIS was assessed by a five-point 
Likert scale for statements regarding: a) satisfaction with the service, b) influence on 
therapeutic decision by the answer provided, and c) recommendation of RELIS’ 
service to colleagues. Clinical impact of the information provided was assessed by 
predefined categories. The physicians were also asked to rank RELIS and other 
commonly used sources in terms of their usefulness in providing drug information 
during pregnancy.  
Paper IV: The questionnaire contained authentic texts relating to pregnancy from the 
PILs for five medicines and one herbal medicine with different indications for use; 
• pivmecillinam (Selexid™) for urinary tract infection 
• metoclopramide (Afipran™) for pregnancy-induced nausea during the 1st
trimester 
• paracetamol (Paracet™) for back pain 
• escitalopram (Cipralex™) for depression during the 1st trimester 
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• valeriana officinalis (Valerina Natt™) herbal medicine for insomnia 
• dexchlorpheniramine (Polaramin™) for seasonal allergy  
Each text was followed by questions regarding:  
• A: teratogenic risk of the medicine described in the text on a scale from 0: 
never teratogenic to 10: always teratogenic 
• B: confidence in taking (pregnant women) or prescribing (GPs) the medicine 
for the given indication (yes or no)  
• C: clarity of the text on a scale from 0: exceptionally clear to 3: exceptionally 
unclear  
We considered the least clinical significant difference between pregnant women and 
GPs assessing teratogenic risk to be two units on the risk scale from 0 to 10. 
3.2.3. Methodological considerations 
Paper II: Selection bias is possible since the responders may not have been 
representative for all physicians. However, a high response rate (76%) may have 
reduced the risk of this bias. The physicians who responded could have felt more 
inclined to share positive than negative views, although anonymous responses might 
have reduced this possible influence. The physicians who contacted RELIS may have 
been more motivated for change in practice compared to those who do not use RELIS. 
The clinical impact of the answers from RELIS was self-assessed by the physicians 
and we have no information as to whether the information was transformed into action. 
Paper IV: Assessments of teratogenic risks and confidence in use of medicines were 
based on hypothetical case descriptions, with conditions or indication as a surrogate 
for a clinical situation. However, if a situation arises in which medical therapy is 
needed during pregnancy, differences in risk perception within the pair could be of 
importance for therapeutic decisions. Selection bias is possible among the pregnant 
women since the level of education and proportion of women taking folic acid was 
higher, and the proportion of smokers and users of herbal medicines lower compared 
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to the general population in Norway. However, this may be explained by recruitment 
from a University Hospital. The responding physicians may have been those with a 
special interest in the topic, and selection bias was therefore also possible among 
physicians. The texts chosen for the questionnaire could have affected the results and 
the indications (for example depression) may have been assessed instead of the actual 
texts.  
3.3. The qualitative study (Paper III) 
3.3.1. Recruitment of participants 
Pregnant WWE, treated with one or more AEDs, who had undergone routine 
ultrasound screening at 18 weeks of pregnancy without observation of teratogenic 
effects, were asked to participate. The women were recruited by a nurse or a 
neurologist at the Neurology Outpatient Clinic, either at Haukeland University 
Hospital in Bergen, Norway, or at Oslo University Hospital in Oslo, Norway.  
3.3.2. Data collection 
All women were interviewed at the Neurology Clinic for approximately one hour. The 
interviews were initiated with a short questionnaire where the participants were asked 
to provide information regarding their age, week of gestation, type of seizure, present 
seizure frequency, number of years since the diagnosis was made, number of previous 
children, and use of AEDs and other medicines. The interview guide was semi-
structured and contained open-ended questions regarding the women’s: 
• Risk perception: experiences and thoughts on using medicines and risking 
seizures in pregnancy, in addition to physicians’ presentation of teratogenic 
risks. 
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• Experiences with and needs for medicines information, including participation 
in decisions regarding therapeutic drug regimens and relations with the health 
care system 
3.3.3. Methodological considerations 
A possible selection bias is that we could not include WWE who theoretically could 
become pregnant, but who had avoided pregnancy because of poorly controlled 
epilepsy or disabilities. In addition, women carrying a fetus diagnosed with a 
teratogenic effect were excluded, due to ethical issues. Performing the interviews 
earlier in pregnancy might have given different results. However, shorter experience of 
pregnancy and possibly higher levels of concern prior to ultrasound examination, 
could have given less consistent findings and less time to reflect over the situation.  
The participating women took part in the follow-up programme for pregnant WWE 
offered through Norwegian hospitals and the results may not be valid in other 
populations.  
3.4. Analysis of data 
3.4.1. Statistical analysis (Papers I, II and IV) 
Paper I: We introduced two different terms to describe the data. The term ‘all advice’ 
included all categories (1-4), while the term ‘grouped advice’ was constructed by 
combining categories 2 and 3 (unsafe and possibly unsafe), preserving category 1 (safe 
use) and excluding category 4 (no information). Introducing the term ‘grouped advice’ 
allowed statistical analysis of the categorized advice using McNemar’s test. Kappa (ț) 
statistics (ț coefficient) were used to calculate observer agreement in a pilot test. P 
values < 0.01 were accepted as statistically significant.  
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Paper II: The answers provided by GPs and hospital physicians (HPs) were compared 
by analysis using a Mann–Whitney U exact test. P values < 0.05 were considered to be 
statistically significant.  
Paper IV: To examine differences between pairs of pregnant women and their GPs, 
data were analysed with mixed linear model analysis (132) for teratogenic risk scores 
(question A) and generalized estimating equations (GEE) (133) for confidence in use 
of medicine (question B) and clarity of the text (question C). Multiple linear and 
logistic regressions were used to examine influence of personal characteristics on the 
parameters. To analyse the relationship between scores for teratogenic risk (question 
A) and non-confidence in use of a medicine (question B), we used simple logistic 
regression. P values  0.05 were accepted as statistically significant.  
3.4.2. Qualitative analysis (Paper III) 
The analysis was performed in accordance with the principles of systematic text 
condensation (134). According to the aims of the study, all three authors defined the 
categories for presenting the results as (1) risk perception and (2) experience with and 
needs for medicines information. Quotes from the women were used to illustrate the 
results. 
3.4.3. Choice of methods for analysis 
As described above, data were analysed using different methods in the studies 
performed. Table VI presents the basis for the choice of methods, in addition to some 
limitations of the chosen methods for analysis. 
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Paper Method  Description of method and reason for choice of method Some limitations of the method
McNemar's test
Suitable for paired proportions of categorical 
data, and categorized advice from two 
information sources were compared.
Designed for use with large samples.                       
Applies only for comparison of two raters. 
Kappa (ț) statistics
Measures inter-rater agreement, and in the 
pilot study it was used to measure agreement 
between raters with different professions
The value of kappa depends on the number of 
categories and the prevalence in each category.      
The method takes no account of the degree of 
disagreement (counteracted by using weighted 
kappa).                
II Mann-Whitney U exact test
A non-parametric comparison of two 
independent groups, and answers of 
physicians with different workplaces were 
compared. 
Limitations of non-parametric methods;                    
Information may be wasted.                                       
Difficult to make quantitative statements about the 
actual difference between groups.
III Systematic text condensation 
A descriptive and explorative method for 
thematic cross-case analysis of qualitative 
data. It was used to explore experiences and 
needs among patients. 
Common limitations with other qualitative methods. 
The cross-case line of thematic analysis and 
decontextualization of data may lose the individual 
context.
Mixed linear model 
analysis
Suitable for outcome variables that have 
continuous correlated responses. It was used 
for comparing responses on a scale from 0-10 in 
correlated data, due to physicians being paired 
with all pregnant patients. 
Implementation of statistical programs to perform 
the analysis.                                                               
The model requires a great deal of ad hoc 
understanding of the phenomena under study.
Generalized 
estimating 
equations (GEE)
Suitable for outcome variables that have 
dichotomous correlated  responses. It was 
used for comparing responses of yes/no or 
ordinal categories from 0 to 3 in correlated data, 
because physicians were paired with all 
pregnant patients.
Challenges with model selection due to lack of 
absolute goodness-of-fit tests to aid comparisons 
among several plausible models.                              
GEE parameter estimates are sensitive to the 
presence of outliers, and estimates are not 
efficient if the correlation structure is mis-specified.
Multiple linear and 
logistic regression
Multiple regression can examine dependence 
of an outcome variable on several other 
variables (in this case: personal characteristics) 
simultaneously. Linear regression was used for 
the continuous variable (scale from 0 to 10) and 
logistic regression for the categorical variables 
(yes/no or ordinal categories from 0-3). 
Significance may occur by chance due to multiple 
testing.                                                                        
Large sample sizes may result in statistical 
significance even for small effects.                            
Difficult to distinguish between additive effects, 
conditional relationships and multiple causal 
pathways of the included variables.
Table VI. Overview of the methods for statistical and qualitative analysis included in the papers.
I
IV
3.5. Ethics and approvals 
Paper III: The study was approved by the Regional Committee for Medical Research 
Ethics and The Norwegian Social Science Data Services. Informed consent was given 
by the participants and the work was carried out in accordance with the Code of Ethics 
of the World Medical Association (Declaration of Helsinki).  
Paper IV: The study was submitted to the Regional Committee for Medical Research 
Ethics, but because the patient data were anonymous, it was concluded that approval 
was not required.  
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4. MAIN RESULTS
4.1. Paper I  
Advice on drug safety in pregnancy – are there differences 
between commonly used sources of information? 
A total of 443 drug advices were categorized, of which 224 were provided in 2003 and 
219 in 2005. For 208 (47%) of the drugs, advice differed between RELIS and FK. 
Advice from FK were significantly (p < 0.01) more restrictive than advice from 
RELIS. There were no differences in the level of consistency between advice; 
• for drugs that were newly introduced or those that had been on the market for a 
longer time (> 8 years) 
• that regarded use of drugs in the first trimester or use in the second or third 
trimester 
• that were provided during 2003 or 2005  
182 (41%) of the questions submitted to RELIS regarding drug use in pregnancy 
concerned drugs acting on the nervous system (ATC- group N), 55 questions (12%), 
concerned drugs acting on the respiratory system (ATC-group R), and 54 questions 
(12%) concerned anti-infectives for systemic use (ATC-group J). Furthermore, seven 
out of ten of the substances most frequently enquired about were drugs acting on the 
nervous system, of which four were SSRIs with citalopram in first place.  
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4.2. Paper II 
Drug use in pregnancy – physicians’ evaluation of quality 
and clinical impact of drug information centres
Of the 162 questionnaires sent to physicians, 123 (76%) were returned, and 117 were 
included in the analysis. 43% of the participants worked in general practice, 35% were 
HPs, 9% worked elsewhere and 14% did not state their practice.  
The majority of the participants strongly agreed with all three statements regarding the 
quality of the service;  
• satisfaction with the answer 
• importance of the answer provided for the therapeutic decision  
• recommendation of RELIS’ service to colleagues  
92% stated that the answer from RELIS had clinical impact on their therapeutic 
decision and 9% reported that termination of pregnancy was avoided as a result of the 
information provided.  
RELIS was ranked highest among the stated sources providing information on drug 
use in pregnancy, followed by product monographs, Norwegian drug and therapeutic 
formulary, colleagues and other sources. GPs ranked the information provided by 
RELIS significantly higher than HPs.  
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4.3 Paper III  
Risk perception and medicines information needs in 
pregnant women with epilepsy – a qualitative study 
Ten pregnant WWE, aged 22-39 years in 20-34 weeks’ gestation, were interviewed. 
All participants stated that avoiding seizures by taking AEDs in pregnancy outweighed 
perceived teratogenic risks and self-reported adherence to AED-therapy was high. 
However, dose adjustments of AEDs during and after pregnancy caused concerns for 
teratogenicity or seizures. Factors that reduced concerns regarding teratogenic effects 
of AEDs included ultrasound examinations, checks of fetal heart rate and movements, 
previous positive experiences of pregnancy outcome, and preconception counselling 
regarding AED therapy. The women reported restrictive attitudes towards taking 
medicines for indications other than epilepsy. 
The participating women were satisfied with the amount of medicines information 
provided, though their needs for medicines information were reduced by long-term use 
of AEDs and restrictive use of other medicines. The women valued their neurologist as 
their primary source for medicines information. Most women browsed the Internet for 
health- and pregnancy- related information in general, although some were sceptical to 
the quality of information on different websites. PILs were read, but were perceived as 
difficult to understand. The women were exceptionally satisfied with the follow-up 
provided by the health care system.    
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4.4. Paper IV  
Teratogenic risk perception and confidence in use of 
medicines in pairs of pregnant women and general 
practitioners based on patient information leaflets  
A total of 300 questionnaires were handed out to pregnant women. 175 responded 
(response rate 58%) and 171 were included. Questionnaires were sent to 121 different 
GPs, of whom two were excluded and 74 responded (62% response rate). Since some 
of the women had the same GP, a total of 98 pairs of pregnant women and GPs were 
identified.  
Pregnant women had significantly higher perceptions of teratogenic risks and lower 
confidence in use of medicines compared with GPs. The differences between 
teratogenic perceptions of texts for escitalopram (mean difference -3.3), valeriana 
officinalis (mean difference -2.4) and metoclopramide (mean difference -2.1) were 
clinically significant according to our definition of minimum 2 units difference. For 
escitalopram, the GP was 9.5 times more likely to have confidence in prescribing the 
medicine than the pregnant woman’s confidence in taking it. In contrast, the 
corresponding odds ratio for dexchlorpheniramine was 2.8.  
Both pregnant women and GPs assessed the teratogenic risks in the texts for 
escitalopram and valeriana officinalis to be highest among the texts, and confidence in 
use of these medicines was the lowest. None of the participants had confidence in use 
of the herbal medicine valeriana officinalis. The texts for dexchlorpheniramine and 
paracetamol were assessed the least teratogenic and were associated with high 
confidence in use of the medicine. Among all participants, there were only minor 
differences in the overall score of clarity of all texts, with the exception of the text for 
escitalopram, which GPs assessed as less clear than the other texts.  
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5. DISCUSSION  
What are the needs for medicines information regarding pregnancy? Through working 
in a DIC, I had observed frequent questions from physicians in doubt about therapeutic 
choices for their pregnant patients. This led me to question whether the available 
information regarding teratogenic drug risks for physicians and their pregnant patients 
was sufficient and appropriate, or whether there were other factors that could explain 
this insecurity. I therefore aimed to explore the needs for medicines information 
among physicians and pregnant women, based on their experiences, attitudes and risk 
perceptions. In the following, I will present the basis for the four studies performed, 
discuss the study results in light of other findings and suggest implications for my 
research.  
5.1. Background for performing the studies included in the 
thesis
To achieve an understanding of the attitudes of and needs for medicines information in 
pregnancy, different methodologies (from descriptive to explorative) were applied on 
different study populations (physicians and pregnant women; healthy and with a 
chronic disease). I first set out to describe and compare advice in medicines 
information sources regarding pregnancy that are commonly used by physicians 
(Paper I). One of the sources included in the comparison was RELIS, and on the basis 
of the findings in the first study, an evaluation of the patient-specific advice regarding 
pregnancy provided by RELIS was sought (Paper II).  
Having based the first two studies on the perspective of physicians, I wanted to 
also examine the attitudes of pregnant women regarding medicines information. By 
interviewing pregnant women using drugs for a chronic disease (epilepsy), a 
qualitative understanding of risk perceptions and needs for medicines information was 
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achieved (Paper III). Finally, it was desirable to explore the possible differences 
between pregnant women and their physicians concerning perceptions of risks on use 
of medicines during pregnancy, and a survey was performed (Paper IV).  
5.2. What are the needs for drug information in pregnancy? 
Several studies have examined needs and desires for drug information in different 
patient populations (65, 135-137) and scales have been developed and validated (137-
140). One example is the Satisfaction with Information about Medicines Scale (SIMS) 
which aims to assess if a person has received enough information about topics related 
to prescribed medicines. Based on SIMS, a high level of satisfaction with medicines 
information is found to be correlated with a high degree of adherence to treatment 
(138). This may also confirm the findings in Paper III; adherence to AEDs and 
satisfaction with drug information was high.  
Information needs may vary not only between individuals, but also for an 
individual at different times depending on diagnosis, state of disease and current 
knowledge (135, 136). Patients also differ as to whether or not they proactively seek 
medicines information (139). Studies indicate that patients who have been treated with 
drugs for a long period of time have a decreased desire for information (135, 136). 
This is in line with the findings in Paper III, where the participants with a chronic 
disease reported reduced needs for medicines information.  
Studies have also found that patients who express desire for drug information are 
less concerned and more empowered after receiving additional information. In 
contrast, those that are less inclined to seek drug information become less empowered 
with increased drug information load, possibly due to a belief that drug therapy is 
better decided by the prescriber (137). This reflects the subjectivity of satisfaction with 
information (139). In Paper III, need for drug information was reduced when the 
follow-up provided by the health care system was of high-quality. Thus, the setting in 
which health information is provided is of importance, as is patients’ relationship to 
and confidence in health care providers. 
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A Norwegian study has shown that drug use is highest among patients with a low 
level of education, possibly due to a greater scepticism to use of medicines among 
persons with a high level of education (141). Furthermore, a low level of education is 
suggested to be associated with a low level of health literacy (142). Health literacy is 
defined by the World Health Organization (WHO) as representing “the cognitive and 
social skills which determine the motivation and ability of individuals to gain access 
to, understand and use information in ways which promote and maintain good health” 
(143). This implies that health literacy means more than just reading comprehension 
and that it can enable patients to take control of their own health. The level of health 
literacy may therefore be an important determinant for patients’ individual needs for 
drug information.  
Health literacy is assessed by use of different tests or scales that are tested for 
reliability (142). Lack of health literacy may have several consequences such as 
incorrect use of medicines and lack of knowledge in health decisions (142). Health 
literacy among pregnant women has recently been studied in a cross-sectional, 
international study. Women with a low level of health literacy had higher teratogenic 
risk perceptions, less frequent use of medicines and reduced adherence compared to 
women with a high level of health literacy (144). This indicates that improving health 
literacy among pregnant women may impact health behaviour. Furthermore, 
unpublished results from this study showed that the level of health literacy among 
pregnant women in Norway is relatively low compared to other Western countries 
(145). Health literacy was not directly measured in Paper IV. Even though the level of 
education among the pregnant women was high, health literacy may be a factor that 
contributes to explaining the differences in risk perception and confidence in use of 
medicines between pregnant women and GPs.  
5.2.1. Risk perceptions and needs for drug information
The findings in Papers III and IV show that risk perceptions are determinants for 
confidence in use of medicines, and others suggest that risk perceptions may influence 
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general health behaviour (64). As described in Section 1.4., factors such as Western 
societies’ increased focus on risks may contribute to pregnant women’s restrictive 
attitude to the use of medicines (73). It could be speculated that since pregnant women 
are expected to refrain from a range of activities that are considered to be dangerous, 
such as eating cheese or painting walls, they may feel they should at least refrain from 
taking any kind of foreign substances such as drugs. Furthermore, people have a 
tendency to overstate risks that have low probability but are dramatic and may have 
serious consequences, such as being in a plane crash. In contrast, they tend to 
underestimate more common risks, for example getting diabetes or hypertension (108). 
The findings in Papers III and IV of increased teratogenic risk perceptions could 
possibly be explained by this phenomenon of small, but dramatic risks being 
overestimated. As described in Section 1.4., distorted risk perceptions may also be due 
to the legacy of the thalidomide tragedy. To counteract the overestimation of risks, a 
greater focus on the positive consequences for the health of mother and child of 
treating medical conditions during pregnancy could be pursued.     
The Beliefs about Medicines Questionnaire (BMQ) is validated for use among 
patients with a range of chronic illnesses. The BMQ contains scales for necessity and 
concerns to assess positive and negative attitudes to use of medicines (146). In one 
study using the BMQ, the necessity-concerns difference scores were strongly 
correlated to adherence, and patients who reported strong concerns about taking 
medicines had lower adherence (147). These findings may be used for interpretations 
of the findings in Paper III; that strong beliefs about the necessity of treatment 
outweighed concerns for negative effects of AEDs in pregnancy. Furthermore, in 
Paper IV, low confidence in use of a medicine, for example for escitalopram, may be a 
reflection of a stronger belief in concerns compared to necessities. Consequently, 
prescribed medicines are not necessarily taken by pregnant women since personal 
beliefs about medicines are major determinants of adherence. 
High teratogenic risk perceptions among pregnant women, as found in Paper IV
and in previous studies (14, 56-62), may be decreased by risk counselling (58, 148). 
Provision of medicines information through counselling may therefore be important 
for realistic teratogenic risk perceptions. 
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5.2.2. Utilization of drug information sources to meet information 
needs  
Physicians value readily available medicines information that is useful for providing 
advice in a clinical setting (80, 149). These preferences regarding medicines 
information sources support the findings of DIC as a valued information source and 
discussion partner (Paper II). The results of Paper II also indicate that information 
provided by DICs may have clinical consequences. Recent studies from DICs in 
Denmark and the UK (89, 90, 150) provide further support to the findings of Paper II. 
The questions to these DICs did not specifically regard drug use in pregnancy, but in 
the Danish study, 31% of the queries concerned pregnancy and 90% of the answers 
resulted in an impact on clinical practice. Furthermore, more than 90% of responders 
were satisfied with the answer (89). In two studies from the UK, about 80% of the 
answers from DIC were used to manage a current patient (90, 150) and 99% of the 
responders reported to be satisfied with the service provided (90).  
The results from Paper IV indicate that phrasing of information texts in PILs 
can influence teratogenic risk perceptions and confidence in use of medicines. 
Physicians may therefore increase pregnant patients’ confidence in prescribed 
medicines if they explain information in PILs that is contradictory to their own 
suggestions concerning drug therapy.  
5.2.3. Inconsistencies between information sources 
As described in Section 1.6., both pregnant women and physicians have access to a 
range of information sources regarding teratogenic drug effects. However, 
misinformation and misconceptions can arise from use of sources that are not updated 
or that provide incorrect advice. Based on the results from Paper I, inconsistencies 
between sources of information may be common. Others have found inconsistencies in 
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patient’s medicines information sources regarding use in pregnancy (112) and that this 
may cause confusion and non-adherence among pregnant women (14).  
After the publication of Paper I, a similar study from Croatia was published. In this 
study, risk assessments by clinical pharmacologists counselling pregnant women were 
compared to the FDA risk categorization system. Agreement of assessments by the 
two sources was found in only 28% of cases, as compared to 53% agreement rate in 
Paper I. The Croatian study also measured pregnancy outcomes, and it was found that 
clinical pharmacologists’ risk assessments were the best predictor for pregnancy 
outcomes (34). The differences in results between the two studies may be explained by 
different methodology. Nevertheless, the common findings emphasize the problems of 
inconsistencies between sources that provide advice regarding drug use in pregnancy.  
The differences found in Paper I and in the Croatian study may to some part be 
expected, and explained by the different standpoints of product-specific and product-
independent sources, as explained in Section 1.6.1.1. However, the clinical 
consequences of differences in advice are important, as the choice of information 
source may impact the physician’s therapeutic decisions, as well as pregnant women’s 
adherence to therapy.  
5.2.4. Antidepressants; special information needs? 
Some estimate that as many as 18% of women are depressed during pregnancy, and 
that up to 13% have an episode of major depression (151). Others suggest that the 
prevalence of major or minor depressive episodes is about 10% (152). Norwegian 
studies indicate that about 1% of pregnant women use antidepressants (12, 153). 
Importantly, antidepressants was the drug group that RELIS received most questions 
about regarding use in pregnancy (Paper I), and other studies have documented 
frequent questions to TIS regarding antidepressants (154, 155). Paper I also showed 
that advice for antidepressants were most discordant when comparing advice from the 
product monograph in FK and RELIS. Furthermore, in Paper IV, risk perceptions 
were highest and confidence in drug use lowest for the antidepressant escitalopram. 
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Others have also shown that confidence in use of antidepressants during pregnancy 
and adherence to therapy is not only low (156, 157), but lower than use of gastric 
drugs and antibiotics during pregnancy. This may be due to pregnant women being 
more concerned about the teratogenic effects of psychotropic drugs than of somatic 
drugs (59). Even physicians may have increased concerns for prescribing psychotropic 
drugs during pregnancy, due to the potential effects on the central nervous system. In 
addition, health care providers do not have unanimous views regarding treatment of 
depression during pregnancy. For example, GPs differ in their attitudes as to whether 
antidepressants should be stopped or continued (83).
The findings in Papers I and IV indicate that physicians and pregnant women 
are particularly insecure about use of antidepressants. A reason for this may be 
difficulties to make benefit/risk assessments on this topic. The benefit of 
antidepressant therapy is that possible impact of depression on the fetus is avoided. 
Such impact may result in preterm delivery, neonatal symptoms and postpartum 
depression - which may adversely affect the interaction between mother and infant. 
Untreated depression may also increase the risk of self-destructive behaviour and 
psychosis during pregnancy (152). In spite of the widespread use of antidepressants, 
and SSRIs in particular, during pregnancy, there are conflicting views on their 
teratogenic risks. Studies on risks of miscarriages, malformations, persistent 
pulmonary hypertension and long-term effects on neurodevelopment have shown 
inconsistent results (83, 158). However, if the risks were to be increased above the 
baseline risk, absolute risks would still be low. What however is known is that use of 
SSRIs late in pregnancy is associated with transient neonatal discontinuation 
symptoms, like many other psychotropic drugs (158). Psychotherapy could be a 
treatment option, either alone or in combination with antidepressants (152).   
To summarize, insecurity regarding therapeutic choices for depression in 
pregnancy may be caused by the unknown consequences of treating or not treating the 
individual woman. An increased focus to provide information regarding different 
aspects of using antidepressants in pregnancy is therefore advisable. Individual factors 
such as a woman’s severity of disease, history of drug use, possible concomitant 
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diseases and risk of self-destructive behaviour, are important determinants for 
treatment choice.  
5.2.5. How should teratogenic risks be presented?  
Medicines information regarding pregnancy inherently conveys teratogenic risks. Both 
in oral and written medicines information, framing of risk information may be 
important for how teratogenic risks are perceived. The same data may be interpreted 
differently by individuals due to different attitudes and risk perceptions, resulting in 
different behaviour (63). Health literacy, as described in Section 5.2., is important for 
understanding and interpreting medicines information and teratogenic risks (159). 
Figure V provides examples of different formats for risk communication, and in the 
following, some of these are further described.  
                    
Visual aids            
(i.e. Cates plot)
Negative vs
Positive framing 
Relative risk
Teratogenic risk 
symbols
1:100 
vs
1%
1 300:10 000              
vs
26:100
Absolute risk
1:1 000                     
vs
«rare»
Risk 
communication
formats
Figure V. Examples of risk communication formats 
Negatively-framed risk information (1-3 % risk of having a child with malformation) 
may result in significantly higher risk perceptions among pregnant women compared 
to positively-framed information (97-99% chance of having a normal child) (160). 
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Relative risks (a 100% higher risk of having a child with a malformation due to drug 
exposure) are intended for comparison of risks in two groups of people, and presenting 
relative risks to individuals may result in overestimation of risks. Absolute risks or 
attributable risks are generally perceived as less concerning; (the normal rate of this 
malformation is 1/1000 children and this drug may result in twice that rate or 2/1000) 
(159). Information in either numeric (1:1000) or mixed numeric/word formats should 
be preferred to exclusively verbal formats (“rare”) since both patients and health care 
providers may have different understanding of the meaning of verbal descriptors (159, 
161). Visual aids for patient’s risk assessments have been developed and Figure VI 
presents an example of such an aid. This matrix may be used to depict the benefits and 
harm of a treatment (161) and may also be used for communication of teratogenic risks 
since the baseline risk is included.  
             
These two people
will suffer harm 
because they
have taken drug X
These two people
will suffer harm 
whether or not 
they take drug X
These 96 
people will not 
experience
harm, just as if
they had not 
taken drug X
Figure VI. A Cates plot in 100 people showing how drug X doubles the risk of an unspecified harm 
compared with no treatment. From Cox et al (161). 
As the results of both Paper IV and previous findings (61) have indicated, phrasing 
and selection of more or less reassuring words and terms can influence risk 
perceptions and confidence in use of medicines. Based on this, there is potential for 
framing information in such a way that realistic risks are perceived.  
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Physicians play a key role in communication and framing of risks to patients 
and the atmosphere in the patient-physician setting is important for how risk 
information is perceived (162). Pregnant WWE had great trust in their neurologist as 
drug information provider and risk communicator (Paper III). However, a crucial 
factor for both patients and physicians is having enough time in the consultation for 
discussion of benefits and risks of treatment (81, 163).  
5.3. Methodological considerations  
Limitations of the respective studies are explained in Section 3.1, 3.2., 3.3., and in the 
respective papers. In the following, I will comment on some methodological 
considerations of the thesis as a whole.  
The studies were performed from the viewpoint of a DIC providing drug advice 
regarding pregnancy. This has probably influenced the choice of study methods as 
well as study objectives. Preconceptions of the researchers may have affected 
interpretation of results, especially for the qualitative study (Paper III). Nevertheless, 
our preconceptions were used to place focus on issues that we had experienced were 
problematic for physicians and pregnant women.  
We chose to use both quantitative (Papers I, II and IV) and qualitative methods 
(Paper III). If Paper III had been omitted, the possibility of exploring life experiences 
of patients would have been lost, and we consider it enriching for the other studies to 
include a qualitative perspective.  
Generalizability, or internal validity, indicates if the study results are 
representative for populations other than the one studied. In Paper I, advice from two 
Norwegian commonly used drug information sources were compared and the results 
may also be valid in countries where corresponding sources are available. Paper II
was based on queries to DICs (RELIS) from physicians, and the results may be 
extended to countries where similar services are established. In Paper III, pregnant 
WWE included in a follow-up programme by the Neurology Clinic at a University 
Hospital were recruited and the results may therefore not be directly extrapolated to 
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other populations. In Paper IV, we recruited all women attending ultrasound 
examination in weeks 17-19 of pregnancy, and their respective GPs. Although the 
responding women differed from the general population in some of their personal 
characteristics, this may be expected based on other findings on the types of persons 
that are inclined to participate in surveys. The results may therefore be valid for 
pregnant women in general in Norway, and in other countries with similar traditions of 
drug use in pregnancy. 
Health care providers other than physicians were not studied in this thesis. As 
described in Section 1.6.2.1., midwives and pharmacists are in contact with pregnant 
women, and a limitation of the thesis is that such health care providers were not 
included.  However, this may be a topic for further research.  
The physician’s own attitudes, beliefs and expectations may influence the 
patient’s health behaviour. In Paper III, we assessed this interaction indirectly through 
patient interviews, but including direct measurements of this interaction in Papers III 
and IV could have improved the thesis.  
5.4. Implications for drug information  
Do people need more drug information or do they need the information that already is 
available to be more clinically useful and understandable? I believe the latter and that 
the main challenge may be that physicians and pregnant women are unaware of where 
to find appropriate information, as confirmed by others (81, 82).  
A factor that complicates use of medicines information relating to pregnancy is 
that experts differ in their interpretation of data and opinions regarding teratogenic 
risks, increasing the risk of differences in advice between information sources. 
Considering this factor, designing one “golden standard” source - disregarding all 
other opinions - is not achievable or even desirable.  
In Figure VI, I suggest a drug information strategy divided into three levels: 
individual, group and national. In the following, the suggestions are further explained. 
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Individual
level
¾ Time to explain and discuss
benefits and risks of therapy
¾ Explain information in PILs
¾ Tailor information to individual
needs and risk perceptions
Group 
level
¾ Electronically available decision
tools and corresponding patient
information
¾ TIS /DIC 
National 
level
¾ Develop electronic decision
tools
¾ Information sites for the
public
¾ Assure availability to DIC 
and TIS 
Figure VI. Drug information strategies to physicians and pregnant women. 
On the individual level, focus on tailoring medicines information according to the 
needs and perceptions of each woman could be desirable as this may increase patient 
satisfaction, empowerment and adherence to drug therapy (135, 139, 164). 
Individualized counselling does however require sufficient time to discuss treatment 
choices and to explain medicines information that the patient will read in the PIL. 
Adequate time for such counselling is especially important in situations where 
unrealistic risk perceptions are likely to be present or when medicines information 
sources differ in their advice.   
When considering the information needs of physicians as a group, electronic 
prescription tools providing information on drug use in pregnancy could be utilized, 
supported by findings that physicians appreciate decision support through 
electronically available systems (81, 149). Such a tool should be expert-evaluated, 
such as the Norwegian drug and therapeutic formulary (“Norsk legemiddelhåndbok for 
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helsepersonell”) (165). The electronic system should include information which could 
be handed to the patient, thus decreasing the risk of inconsistent information. The 
same system, with corresponding information for prescriber and patient, should also be 
available online. Considering the increasing technical possibilities of designing online 
information, I expect that future online medicines information relating to pregnancy 
could be dynamic and interactive.   
Another suggestion is a further focus on patient-specific information provided 
by DIC and TIS, as this has been shown to be appreciated by both the public and 
health care providers. DIC and TIS may be particularly important as sources of 
information and discussion partners for benefit/risk assessment of drug therapy for 
pregnant women with chronic diseases.  
On a national level, availability of appropriate information sources that are 
independent of the pharmaceutical industry, including DIC, TIS and electronic 
decision tools, should be assured. There are already governmental Internet- sites 
established for public information services (166). These sites also contain information 
for pregnant women, although currently little advice regarding use of medicines (123). 
Such sites could however be utilized for medicines information systems for both 
prescribers and patients, as suggested above. In the future, Facebook and Twitter may 
also be utilized as channels for medicines information relating to pregnancy. 
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6. CONCLUSIONS  
Both pregnant women and physicians need medicines information that can help them 
make the right therapeutic decisions. The results of the studies included in this thesis 
indicate that:  
• Sources of information differ in advice regarding drug use in pregnancy 
• DICs are a valuable source of information for physicians seeking advice for 
counselling pregnant women 
• Pregnant WWE consider the benefits of AED-treatment to outweigh teratogenic 
risks, but are concerned for dose adjustments  
• Pregnant women have higher teratogenic risk perceptions and lower confidence 
in use of medicines compared to physicians. Phrasing of information texts can 
influence risk perceptions and confidence in use of medicines.
Consequently, several factors may influence choices of whether or not to prescribe or 
use medicines in pregnancy: 
• Perceived teratogenic risk of medicines 
• Phrasing of medicines information and framing of risk information  
• Differences in advice between sources of information 
• Availability of information sources that are independent of producers of 
medicines, and that provide patient-specific advice
These factors therefore need to be considered when designing medicines information 
that aims to meet information needs and impact health behaviour. At the individual 
level, medicines information should be tailored according to the pregnant woman’s 
risk perception level and desire for information. 
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7. FUTURE PERSPECTIVES  
Based on the results of this thesis, the following research questions are suggested: 
• How do variations in wording in patient information texts regarding use of 
drugs in pregnancy influence pregnant women’s risk perceptions? 
• How should information regarding use of OTC drugs be provided to pregnant 
women?  
• What kind of medicines information do pharmacists need in order to provide 
appropriate advice to pregnant women? 
• Are needs for medicines information among pregnant women with chronic 
diseases different to the needs of pregnant women in general? 
• What is the impact of medicines information relating to pregnancy provided on 
governmental Internet- sites? 
Several of the suggested studies could benefit from the application of qualitative 
methods. 
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